Anchored in patent licensed from Rosalind Franklin University of Medicine and Science, NeuroLucent is focused on developing small-molecule therapeutics to treat the cognitive loss associated with Alzheimer's disease. Targeting Ca2+ dysregulation, an established hallmark of AD neurons, NeuroLucent personnel have uncovered a key intracellular Ca2+ channel that is over-expressed and hyperactive in AD neurons. With the firm now focused on identifying a clinical candidate, preclinical validation has been achieved through the identification of compounds that normalize Ca2+ levels and decrease disease markers in animal models.
